Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
XAIR 
Beyond Air Inc (XAIR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: XAIR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.33
1 Year Target Price $10.33
| 1 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -66.71% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.64M USD | Price to earnings Ratio - | 1Y Target Price 10.33 |
Price to earnings Ratio - | 1Y Target Price 10.33 | ||
Volume (30-day avg) 5 | Beta 0.34 | 52 Weeks Range 0.67 - 10.40 | Updated Date 01/9/2026 |
52 Weeks Range 0.67 - 10.40 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.56 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -421.4% |
Management Effectiveness
Return on Assets (TTM) -49.72% | Return on Equity (TTM) -178.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10828255 | Price to Sales(TTM) 1.32 |
Enterprise Value 10828255 | Price to Sales(TTM) 1.32 | ||
Enterprise Value to Revenue 1.87 | Enterprise Value to EBITDA -4.23 | Shares Outstanding 8009488 | Shares Floating 6641307 |
Shares Outstanding 8009488 | Shares Floating 6641307 | ||
Percent Insiders 5.78 | Percent Institutions 19.82 |
Upturn AI SWOT
Beyond Air Inc
Company Overview
History and Background
Beyond Air Inc. was founded in 2012 with a focus on developing novel medical technologies. A significant milestone was its initial public offering (IPO) in 2019. The company has evolved its focus to primarily address respiratory conditions.
Core Business Areas
- Pulmonary and Lung Diseases: Developing and commercializing innovative treatments for respiratory diseases. This includes a focus on conditions like COPD and asthma, leveraging their proprietary technologies.
Leadership and Structure
Beyond Air Inc. is led by a management team with expertise in the medical device and pharmaceutical industries. The organizational structure is typical of a growth-stage biotechnology company, with departments for research and development, clinical affairs, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- LungFit PH: A device designed to deliver inhaled nitric oxide (iNO) for treating pulmonary hypertension. The market for respiratory devices is competitive, with players like Medtronic and GE Healthcare. Specific market share data for LungFit PH is not publicly available, but the pulmonary hypertension market is substantial.
- LungFit GO: A portable device intended for the treatment of respiratory conditions. This product aims to offer convenience and accessibility for patients. Competitors include companies offering nebulizers and other portable respiratory devices.
Market Dynamics
Industry Overview
The medical device and respiratory care market is characterized by rapid technological advancement, stringent regulatory requirements, and a growing demand for innovative treatments for chronic respiratory diseases. The market is driven by an aging population, increasing prevalence of respiratory illnesses, and advancements in healthcare technology.
Positioning
Beyond Air Inc. positions itself as an innovator in respiratory care, focusing on addressing unmet medical needs with its proprietary technologies. Its competitive advantages lie in its unique product development approach and its focus on non-pharmacological treatments for respiratory conditions.
Total Addressable Market (TAM)
The total addressable market for respiratory devices and treatments is significant, estimated to be in the billions of dollars globally. Beyond Air Inc. is positioned to capture a segment of this market by offering novel solutions for conditions like pulmonary hypertension and chronic obstructive pulmonary disease (COPD).
Upturn SWOT Analysis
Strengths
- Proprietary technology platform
- Focus on unmet medical needs in respiratory care
- Experienced management team
- Potential for multiple product applications
Weaknesses
- Limited commercialization history
- Reliance on regulatory approvals
- Need for significant capital investment
- Early-stage product development for some offerings
Opportunities
- Growing prevalence of respiratory diseases
- Increasing demand for non-invasive treatments
- Potential for strategic partnerships and collaborations
- Expansion into new geographic markets
Threats
- Intense competition from established players
- Regulatory hurdles and delays
- Reimbursement challenges
- Technological obsolescence
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Medtronic plc (MDT)
- GE Healthcare Technologies Inc. (GEHC)
- Koninklijke Philips N.V. (PHG)
Competitive Landscape
Beyond Air Inc. faces a competitive landscape with established medical device and healthcare technology companies. Its advantages lie in its specialized focus on novel respiratory treatments, potentially offering differentiated solutions. However, competitors often have broader product portfolios, larger sales forces, and more established market presence.
Growth Trajectory and Initiatives
Historical Growth: Historically, Beyond Air Inc.'s growth has been characterized by advancements in its product pipeline, clinical trial progress, and regulatory submissions. Revenue growth, if any, would be emerging as products near or achieve commercialization.
Future Projections: Future growth projections are largely dependent on the successful commercialization of its key products, market penetration, and the expansion of its product portfolio. Analyst estimates would typically focus on projected revenue growth and profitability timelines.
Recent Initiatives: Recent initiatives likely include advancing clinical trials for its lead products, seeking regulatory approvals, building out its commercial infrastructure, and potentially exploring strategic partnerships to accelerate market entry.
Summary
Beyond Air Inc. is a biotechnology company focused on respiratory health, with promising technologies like LungFit PH. Its strengths lie in its innovative approach to unmet medical needs. However, it faces significant challenges from established competitors, regulatory hurdles, and the need for substantial capital investment to achieve widespread commercial success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Industry Market Research Reports
- Financial News and Analysis Websites
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Data may be subject to change and may not be entirely comprehensive. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Beyond Air Inc
Exchange NASDAQ | Headquaters Garden City, NY, United States | ||
IPO Launch date 2017-09-22 | CEO & Chairman of the Board Mr. Steven Adam Lisi | ||
Sector Healthcare | Industry Medical Devices | Full time employees 61 | Website https://www.beyondair.net |
Full time employees 61 | Website https://www.beyondair.net | ||
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.